Literature DB >> 15294135

Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.

Michael Hutton1, Eileen McGowan.   

Abstract

The report by Oddo and colleagues in this issue of Neuron demonstrates for the first time that clearance of amyloid also results in the removal of early-stage tau pathology in mice that develop both amyloid plaques and neurofibrillary tangles (NFT), the two hallmark lesions of Alzheimer's disease (AD). This result supports a primary role for Abeta in AD etiology. Copyright 2004 Cell Press

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294135     DOI: 10.1016/j.neuron.2004.07.023

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  5 in total

1.  Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Authors:  John Hardy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

2.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

3.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

Review 4.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

5.  Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.

Authors:  Toru Hiratsuka; Shinsuke Matsuzaki; Shingo Miyata; Mitsuhiro Kinoshita; Kazuaki Kakehi; Shinji Nishida; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.